Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Ross Soo



Author of

  • +

    IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer (ID 284)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 1
    • +

      IS07.02 - Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer (ID 4340)

      16:45 - 17:45  |  Presenting Author(s): Ross Soo

      • Abstract

      Abstract not provided

  • +

    P84 - Targeted Therapy - Clinically Focused - ALK (ID 261)

    • Event: WCLC 2020
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      P84.09 - Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC (ID 3566)

      00:00 - 00:00  |  Presenting Author(s): Ross Soo

      • Abstract
      • Slides

      Introduction

      Lorlatinib is a selective, potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1. In a global Phase II trial, lorlatinib showed substantial overall and intracranial activity in patients with ALK- or ROS1-positive advanced non-small cell lung cancer (NSCLC). Here we report the efficacy and biomarkers of lorlatinib from the Asian subgroup analysis of this trial.

      Methods

      In this ongoing, open-label, Phase II trial (NCT01970865), eligible patients with ALK- or ROS1-positive advanced NSCLC, with or without central nervous system (CNS) metastases were enrolled into six different expansion cohorts based on their ALK and ROS1 status and previous therapy, and received lorlatinib 100 mg once daily. The primary study endpoint was objective tumor response and intracranial (IC) tumor response. Efficacy analyses were conducted for Asian patients (based on race) with ALK-positive NSCLC, who received at least one previous ALK tyrosine kinase inhibitor (this is the first presentation with new data cut-off May 14, 2019). Correlation analyses with tumor tissue and cfDNA ALK resistance mutations are ongoing.

      Results

      Baseline characteristics of the 70 Asian patients (61% female, 51 years median age, 41%/54%/4% ECOG Performance Status 0/1/2, 57% brain metastases at baseline) were similar to the overall population (59% female, 53 years median age, 45%/52%/4% ECOG Performance Status 0/1/2, 67% brain metastases at baseline). Efficacy results of the total Asian population (summarized in Table 1) were similar to the overall population; with ORR of 56% versus 47%, IC-ORR of 59% versus 63% and median PFS of 8.2 versus 7.3 months, respectively.


      table 1.jpg

      Conclusion

      Lorlatinib exhibited similar efficacy in this Asian subgroup compared with the overall population.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    PL01 - Opening Plenary Session (Japanese, Mandarin, Spanish Translation Available) (ID 140)

    • Event: WCLC 2020
    • Type: Plenary
    • Track: N.A.
    • Presentations: 1
    • +

      PL01.03 - Chair (ID 4394)

      18:00 - 20:00  |  Presenting Author(s): Ross Soo

      • Abstract

      Abstract not provided

  • +

    PL05 - Affordable and Accessible Lung Cancer Care (Japanese, Mandarin, Spanish Translation Available) (ID 146)

    • Event: WCLC 2020
    • Type: Plenary
    • Track: N.A.
    • Presentations: 1
    • +

      PL05.02 - Chair (ID 3927)

      18:00 - 20:00  |  Presenting Author(s): Ross Soo

      • Abstract

      Abstract not provided